CW Advisors LLC Acquires 4,336 Shares of Insulet Corporation $PODD

Key Points

• CW Advisors LLC increased its position in Insulet Corporation by 30.8% during the first quarter, accumulating a total of 18,413 shares valued at approximately $4.84 million.
• Multiple large investors have also significantly increased their stakes in Insulet, including Larson Financial Group, which grew its holding by 426.3% during the same period.
• Insulet reported $1.17 EPS for the most recent quarter, exceeding analysts' expectations of $0.92 and marking a 32.9% increase in quarterly revenue year-over-year.

CW Advisors LLC increased its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 30.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,413 shares of the medical instruments supplier's stock after purchasing an additional 4,336 shares during the quarter. CW Advisors LLC's holdings in Insulet were worth $4,837,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Brooklyn Investment Group grew its holdings in Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock worth $209,000 after acquiring an additional 52 shares during the last quarter. OLD National Bancorp IN boosted its stake in shares of Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock valued at $231,000 after purchasing an additional 55 shares in the last quarter. Cooper Financial Group boosted its stake in shares of Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after purchasing an additional 58 shares in the last quarter. Syon Capital LLC boosted its stake in shares of Insulet by 5.6% during the 4th quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock valued at $291,000 after purchasing an additional 59 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 59 shares in the last quarter.

Insulet Stock Performance

Shares of PODD traded up $3.38 during mid-day trading on Thursday, hitting $337.73. 285,682 shares of the company traded hands, compared to its average volume of 757,666. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a 50-day moving average price of $302.59 and a two-hundred day moving average price of $286.87. Insulet Corporation has a 1 year low of $199.68 and a 1 year high of $337.26. The stock has a market cap of $23.77 billion, a price-to-earnings ratio of 102.61, a P/E/G ratio of 2.78 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period in the previous year, the company earned $0.55 earnings per share. The firm's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PODD. Canaccord Genuity Group lifted their target price on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Raymond James Financial reissued an "outperform" rating and set a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Barclays boosted their price objective on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Truist Financial started coverage on shares of Insulet in a research note on Monday, June 16th. They set a "buy" rating and a $365.00 price objective on the stock. Finally, Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a research note on Tuesday, May 13th. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.